Westlake Therapeutics is a biotech company focused on developing red blood cell-based therapies, the first biotech company originating from the laboratory work at Westlake University. We have pioneered the innovative REDx platform, enabling the engineering of natural red blood cells with various drug modalities. Our robust pipeline includes cutting-edge cellular therapies targeting cancer, autoimmune diseases, and metabolic disorders. Our lead product, WTX-212 (Erythrocyte-αPD-1 antibody conjugate), is currently in clinical trials for cancer patients who have not responded to immunotherapy. WTX-212 has demonstrated promising anti-tumor responses in patients resistant to PD-1/PD-L1 immunotherapies, achieving complete remission in cancer patients.Additionally, we operate a fully owned manufacturing facility in Shanghai to efficiently meet patient demand.
